📊 INFU Key Takeaways
Is InfuSystem Holdings, Inc (INFU) a Good Investment?
InfuSystem demonstrates solid operational fundamentals with strong profitability improvements and exceptional cash generation. The company maintains a healthy balance sheet with conservative leverage (0.34x D/E), robust liquidity (1.80x current ratio), and impressive free cash flow conversion at 16.6% of revenue. While modest revenue growth of 6.4% YoY warrants attention, the dramatic 182.6% net income growth and strong interest coverage of 26.1x indicate improving operational efficiency and financial stability.
InfuSystem shows a solid fundamental profile with steady revenue growth, a sharp improvement in net income, and unusually strong free cash flow generation relative to sales. The balance sheet appears healthy, with manageable leverage, good liquidity, and strong interest coverage, although margin expansion and sustained growth will need to continue to support a stronger conviction.
Why Buy InfuSystem Holdings, Inc Stock? INFU Key Strengths
- Exceptional net income growth of 182.6% YoY with diluted EPS up 181.8% demonstrates significant operational leverage
- Outstanding free cash flow generation of $23.8M (16.6% FCF margin) with minimal capex requirements, providing financial flexibility
- Conservative capital structure with 0.34x debt-to-equity ratio and 26.1x interest coverage, indicating low financial risk
- Strong liquidity position with 1.80x current ratio and 1.53x quick ratio, supporting operational needs
- Respectable gross margin of 56.0% suggests pricing power and operational efficiency in the medical device sector
- Strong cash generation, with $23.85M of free cash flow and a 16.6% FCF margin
- Healthy financial position supported by 1.80x current ratio, low 0.34x debt-to-equity, and 26.1x interest coverage
- Profitability improved materially year over year, with net income up 182.6% and ROE reaching 11.6%
INFU Stock Risks: InfuSystem Holdings, Inc Investment Risks
- Modest revenue growth of 6.4% YoY raises concerns about top-line expansion and market demand in competitive surgical instruments market
- Low absolute cash balance of $3.2M relative to total liabilities of $43.2M creates potential liquidity constraints if operating cash flow deteriorates
- Net profit margin of 4.6% remains thin, leaving limited margin for error or unexpected operational challenges
- Operating margin of 8.3% is modest for the medical device sector, suggesting limited pricing power or operational leverage at scale
- Minimal insider activity (1 Form 4 filing in 90 days) provides limited insight into management confidence levels
- Revenue growth remains moderate at 6.4%, which may limit upside if expansion slows further
- Operating and net margins are still relatively modest at 8.3% and 4.6%, leaving less room for execution mistakes
- Cash on hand is relatively low at $3.19M, which could reduce flexibility despite strong ongoing cash flow
Key Metrics to Watch
- Revenue growth trajectory and market share trends in surgical/medical instrument segment
- Operating margin expansion potential as scale increases and operational leverage improves
- Sustained free cash flow generation and capital deployment strategy for growth investments
- Debt reduction progress and cash balance build to strengthen financial flexibility
- Operating margin and net margin progression
- Revenue growth and free cash flow conversion
InfuSystem Holdings, Inc (INFU) Financial Metrics & Key Ratios
💡 AI Analyst Insight
InfuSystem Holdings, Inc presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
INFU Profit Margin, ROE & Profitability Analysis
INFU vs Healthcare Sector: How InfuSystem Holdings, Inc Compares
How InfuSystem Holdings, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is InfuSystem Holdings, Inc Stock Overvalued? INFU Valuation Analysis 2026
Based on fundamental analysis, InfuSystem Holdings, Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
InfuSystem Holdings, Inc Balance Sheet: INFU Debt, Cash & Liquidity
INFU Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: InfuSystem Holdings, Inc's revenue has grown significantly by 40% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.11 reflects profitable operations.
INFU Revenue Growth, EPS Growth & YoY Performance
INFU Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $35.3M | $1.4M | $0.07 |
| Q2 2025 | $33.7M | -$395.0K | $-0.02 |
| Q1 2025 | $32.0M | -$267.0K | $-0.01 |
| Q3 2024 | $31.9M | $689.0K | $0.03 |
| Q2 2024 | $31.7M | $111.0K | $0.01 |
| Q1 2024 | $30.4M | -$324.0K | $-0.02 |
| Q3 2023 | $27.3M | -$89.0K | $0.00 |
| Q2 2023 | $27.0M | $111.0K | $-0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
InfuSystem Holdings, Inc Dividends, Buybacks & Capital Allocation
INFU SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for InfuSystem Holdings, Inc (CIK: 0001337013)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INFU
What is the AI rating for INFU?
InfuSystem Holdings, Inc (INFU) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INFU's key strengths?
Claude: Exceptional net income growth of 182.6% YoY with diluted EPS up 181.8% demonstrates significant operational leverage. Outstanding free cash flow generation of $23.8M (16.6% FCF margin) with minimal capex requirements, providing financial flexibility. ChatGPT: Strong cash generation, with $23.85M of free cash flow and a 16.6% FCF margin. Healthy financial position supported by 1.80x current ratio, low 0.34x debt-to-equity, and 26.1x interest coverage.
What are the risks of investing in INFU?
Claude: Modest revenue growth of 6.4% YoY raises concerns about top-line expansion and market demand in competitive surgical instruments market. Low absolute cash balance of $3.2M relative to total liabilities of $43.2M creates potential liquidity constraints if operating cash flow deteriorates. ChatGPT: Revenue growth remains moderate at 6.4%, which may limit upside if expansion slows further. Operating and net margins are still relatively modest at 8.3% and 4.6%, leaving less room for execution mistakes.
What is INFU's revenue and growth?
InfuSystem Holdings, Inc reported revenue of $143.4M.
Does INFU pay dividends?
InfuSystem Holdings, Inc does not currently pay dividends.
Where can I find INFU SEC filings?
Official SEC filings for InfuSystem Holdings, Inc (CIK: 0001337013) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INFU's EPS?
InfuSystem Holdings, Inc has a diluted EPS of $0.31.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INFU a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, InfuSystem Holdings, Inc has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is INFU stock overvalued or undervalued?
Valuation metrics for INFU: ROE of 11.6% (sector avg: 15%), net margin of 4.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INFU stock in 2026?
Our dual AI analysis gives InfuSystem Holdings, Inc a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INFU's free cash flow?
InfuSystem Holdings, Inc's operating cash flow is $24.4M, with capital expenditures of $560.0K. FCF margin is 16.6%.
How does INFU compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.6% (avg: 12%), ROE 11.6% (avg: 15%), current ratio 1.80 (avg: 2).